Point-of-Care Immunoassay Analyzer Market (2026 - 2033)

Point-of-Care Immunoassay Analyzer Market Summary

The global point-of-care immunoassay analyzer market size was valued at USD 1.2 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 2.3 billion by 2033, at a CAGR of 8.6% from 2026 to 2033. North America dominated the market, accounting for the revenue share of 38.4% in 2025. The market is benefiting from the broader shift toward decentralized diagnostic workflows, as healthcare providers seek to perform quantitative immunoassays closer to the point of care.

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

To learn more about this report, Download Free Sample Report

Market Dynamics

Market Concentration & Characteristics

The global market demonstrates a high degree of innovation, driven by advances in assay sensitivity, analyzer miniaturization, whole-blood testing, automation, and digital connectivity. Manufacturers are developing compact systems capable of delivering laboratory-comparable quantitative results within minutes, supporting the decentralization of cardiac, infectious-disease, inflammatory, and other biomarker testing. Innovation also includes single-use assay formats, broader testing menus, simplified workflows, and connectivity with clinical information systems. For instance, in January 2025, bioMérieux announced its acquisition of SpinChip Diagnostics, which had developed a compact benchtop immunoassay platform capable of delivering results from whole-blood samples in under 10 minutes. Its initial assay menu focuses on high-sensitivity troponin I, NT-proBNP, and D-dimer. This development demonstrates continued innovation in analytical sensitivity, testing speed, platform portability, and near-patient diagnostic capabilities.

The point-of-care immunoassay analyzer industry demonstrates a medium level of M&A activity. Transactions remain selective, with established diagnostics companies acquiring specialized technologies to strengthen rapid-testing portfolios, expand assay capabilities, and increase their presence across decentralized healthcare settings. For instance, in July 2024, Roche completed the acquisition of LumiraDx’s point-of-care technology platform following receipt of the required regulatory and antitrust clearances. The agreement included a purchase consideration of USD 295 million and up to USD 55 million in additional funding through transaction completion. LumiraDx’s portable microfluidic platform supports immunofluorescence assays for biomarkers such as D-dimer, NT-proBNP, and C-reactive protein. The acquisition expanded Roche’s near-patient testing capabilities and intensified competition among diagnostics manufacturers seeking to integrate compact analyzers, diversified assay menus, rapid turnaround times, and laboratory-comparableanalytical performance.

To learn more about this report, Download Free Sample Report

Regulations have a significant impact on the market. Globally, manufacturers must navigate country-specific requirements covering device classification, premarket authorization, analytical and clinical performance validation, quality management, labeling, operator competency, and post-market surveillance. Differences among the U.S. FDA framework, the European Union’s IVDR, and other national approval systems increase compliance expenditure and can extend international commercialization timelines. For instance, in December 2025, the U.S. FDA granted 510(k) clearance under K251074 for Truvian Health’s TruSystem and Tru Liver Health Test Panel. The automated benchtop platform integrates clinical chemistry, immunoassay, and hematology measurements from lithium-heparinized venous whole blood for laboratory and point-of-care use. This clearance demonstrates how regulatory validation facilitates market entry while establishing performance and quality benchmarks that influence product development and commercialization strategies across international markets.

Product expansion is strengthening the global market. Manufacturers are expanding their portfolios with compact platforms that offer broader assay menus, whole-blood compatibility, shorter turnaround times, automated workflows, and clinical information system connectivity. These developments are increasing the applicability of fluorescence- and chemiluminescence-based systems across infectious-disease, inflammatory, cardiac, endocrine, and metabolic testing. For instance, in February 2025, Wondfo Biotech introduced its new Finecare immunofluorescence platform at Medlab Middle East in Dubai. The platform supports whole-blood testing and provides high-sensitivity cardiac troponin I results within eight minutes, supporting time-sensitive clinical assessment in emergency and acute-care settings. This portfolio expansion strengthens Wondfo’s position in rapid cardiac testing and intensifies competition among manufacturers developing compact analyzers capable of delivering quantitative results at the point of care.

Regional expansion is broadening the global footprint of the point-of-care immunoassay analyzer industry. Manufacturers are extending commercial reach through international distribution networks, country-specific regulatory approvals, localized service capabilities, and compact platforms suited to decentralized testing environments. These strategies support revenue diversification and improve access to rapid immunoassay testing across developed and emerging markets. For instance, in September 2025, Siemens Healthineers announced the broad global availability of its Atellica DT 250 benchtop drug-testing analyzer, with availability varying by country. The system provides an immunoassay menu of more than 65 tests, processes up to 225 results per hour, and delivers initial results within eight minutes. Its international rollout expands access to automated drug and therapeutic-monitoring assays while intensifying competition across clinical, forensic, military, workplace, and treatment-center testing settings.

Analyst Perspective

The point-of-care immunoassay analyzer market is expected to grow strongly over the forecast period, driven by increasing demand for rapid clinical decision-making and the continued decentralization of diagnostic testing. Advances in assay sensitivity, analyzer miniaturization, whole-blood testing, workflow automation, and digital connectivity are strengthening adoption across emergency departments, outpatient facilities, and ambulatory care settings. Selective acquisitions are enabling established diagnostics manufacturers to access specialized technologies, while platform launches and assay-menu expansion are broadening the market’s clinical applications. Geographic expansion is further improving product availability across developed and emerging markets. However, differences in regulatory pathways, performance validation standards, and quality control requirements may increase compliance costs and delay commercialization. Innovation and portfolio expansion are expected to remain the principal growth catalysts, while targeted consolidation and regulatory scrutiny are likely to increase as near-patient testing becomes more widely adopted.

Type Insights

The compact benchtop analyzer segment led the market with the largest revenue share of 53.8% in 2025. The segment benefits from its balance of laboratory-comparable analytical performance, moderate throughput, limited space requirements, and suitability for emergency departments, outpatient centers, and physician-office laboratories. These systems commonly support the measurement of endocrine, cardiac, fertility, inflammatory, and infectious disease biomarkers using automated cartridge-based workflows. For instance, in June 2025, Poclight Biotechnology expanded its compact C5000 chemiluminescence immunoassay platform, which has an A4-sized footprint, weighs approximately 7 kilograms, and accommodates seven simultaneous testing channels. The availability of space-efficient analyzers with broader assay menus allows healthcare facilities to internalize testing previously outsourced to central laboratories, thereby sustaining segment revenue and supporting wider adoption of point-of-care immunoassay testing.

The handheld & portable analyzer segment is expected to grow at the fastest CAGR over the forecast period. Growth is supported by increasing demand for bedside testing, mobile healthcare delivery, ambulance-based diagnostics, and biomarker measurement in primary-care and resource-constrained settings. Battery operation, wireless connectivity, small sample requirements, and disposable cartridges enable these analyzers to reduce dependence on infrastructure and extend quantitative immunoassay testing beyond conventional facilities. For instance, in June 2026, Proxim Diagnostics completed the development of its Profile handheld point-of-care immunodiagnostic platform, including the reader, disposable cartridge, and initial manufacturing capacity. The system is being developed to support multiple immunoassay formats, with initial work demonstrating high-sensitivity measurement of troponin I. Continued development of portable platforms with central-laboratory-level sensitivity is expected to expand decentralized testing and accelerate segment growth.

Analyzer Type Insights

The dedicated immunoassay analyzer segment led the market with the largest revenue share of 67.7% in 2025. Dedicated systems remain widely adopted because their hardware, calibration, reagents, and software are optimized specifically for immunoassay workflows, supporting consistent analytical performance and simplified quality control. Closed reagent systems, automated processing, and established menus covering hormones, cardiac markers, inflammation, and infectious diseases strengthen utilization across decentralized laboratories and clinical departments.

The multifunction POCT analyzers with immunoassay capability segment is expected to grow at the fastest CAGR of 10.6% over the forecast period. These systems consolidate immunoassay, clinical chemistry, hematology, and other diagnostic functions within a common platform, reducing instrument duplication, sample handling, maintenance requirements, and laboratory space utilization. Their operational advantages are particularly relevant to outpatient clinics, emergency departments, and smaller healthcare facilities that require broad testing capabilities with limited technical resources. For instance, in November 2025, Ozelle introduced its next-generation AI-enabled Complete Blood Morphology solution at MEDICA 2025, incorporating hematology, biochemistry, and immunoassay testing within an integrated platform for clinical and point-of-care environments. The convergence of multiple testing disciplines is improving workflow efficiency and supporting comprehensive near-patient assessment, positioning multifunction analyzers as an increasingly important contributor to overall market expansion.

Detection Technology Insights

The fluorescence segment led the market with the largest revenue share of 46.8% in 2025. Fluorescence immunoassays combine quantitative detection, relatively short turnaround times, compact instrumentation, and compatibility with whole blood, serum, and plasma. These characteristics support their widespread use as cardiac markers, indicators of inflammation, hormones, and infectious diseases, and in toxicology testing across hospitals, clinics, and mobile settings. For instance, in September 2025, BHR Biosynex secured exclusive UK distribution rights for the AFR-900 fluorescence immunoassay analyzer from Hangzhou AllTest Biotech. The portable platform weighs less than 1.5 kilograms, incorporates a rechargeable battery, and is intended for deployment in hospitals, clinics, general practices, and ambulances. Continued commercialization of lightweight fluorescence readers is strengthening testing accessibility and supporting the technology segment’s leading revenue contribution.

The chemiluminescence segment is expected to grow at the fastest CAGR of 11.7% over the forecast period. Growth is being driven by the migration of high-sensitivity chemiluminescence technology from centralized laboratories to compact analyzers suitable for decentralized settings. The technology provides broad analytical ranges and sensitivity for endocrine, fertility, inflammatory, and infectious disease biomarkers, supporting clinical applications that require precise quantitative measurement. For instance, in November 2025, Shanghai Kehua Bio-Engineering introduced the Polaris V150 automated chemiluminescence immunoassay analyzer at MEDICA. The compact platform delivers up to 150 tests per hour and is well-suited for laboratories that require automated immunoassay capacity in a smaller footprint. The increasing availability of compact, higher-throughput chemiluminescence systems is reducing traditional infrastructure barriers and expanding the technology’s role in the point-of-care immunoassay analyzer industry.

Application Insights

The cardiac disease testing segment led the market with the largest revenue share of 23.9% in 2025. The segment’s leadership reflects the time-sensitive nature of myocardial infarction and heart-failure assessment, which requires rapid measurement of troponin, NT-proBNP, D-dimer, CK-MB, and related biomarkers. Emergency departments and acute-care facilities increasingly use near-patient testing to shorten diagnostic pathways and support earlier treatment decisions. For instance, in September 2026, bioMérieux launched the SPINCHIP point-of-care platform with its first assay, SPINCHIP hs-cTnI, for high-sensitivity measurement of cardiac troponin I from a single drop of blood. The platform extends sensitive cardiac biomarker testing beyond traditional central laboratory workflows. Continued product development focused on faster, whole-blood cardiac testing is expected to preserve the segment’s leading contribution to market revenue.

The inflammation & sepsis testing segment is expected to grow at the fastest CAGR over the forecast period. Rising sepsis awareness and the clinical need to distinguish bacterial inflammation from other conditions are increasing the demand for rapid measurement of procalcitonin, C-reactive protein, interleukin-6, serum amyloid A, and related biomarkers. Near-patient results can support patient risk assessment, antimicrobial decisions, and monitoring within emergency and critical care workflows. For instance, in July 2025, India’s Department of Science and Technology reported the development of a low-cost point-of-care electrochemical biosensor for detecting endotoxin, a biomarker associated with Gram-negative infection and sepsis. Although the system remains a developmental prototype, it demonstrates continued investment in rapid sepsis-biomarker detection. Innovation in multiplexing, assay sensitivity, and whole-blood testing is expected to broaden clinical utilization and drive growth in this application segment.

End Use Insights

The hospitals and clinics segment led the market with the largest revenue share of 61.8% in 2025. Hospitals and clinics generate substantial testing volumes across emergency medicine, cardiology, critical care, infectious diseases, endocrinology, and outpatient services, supporting recurring demand for analyzers and proprietary assay consumables. These facilities also possess the clinical governance, trained personnel, connectivity infrastructure, and quality-control capabilities required to operate quantitative point-of-care systems. For instance, in June 2025, WIZ Biotech presented its WIZ-A101 portable immunoassay analyzer as part of a primary-care diagnostic solution intended for healthcare providers and decentralized facilities. The compact system is designed to provide quantitative results through simplified workflows requiring limited operator training. Continued integration of portable immunoassay platforms into hospital and clinic workflows is expected to sustain the segment’s dominant contribution to market growth.

To learn more about this report, Download Free Sample Report

The diagnostic laboratories segment is expected to grow at the fastest CAGR over the forecast period, driven by increasing demand for rapid quantitative biomarker testing, expanding test menus, and the adoption of compact automated analyzers in decentralized and satellite laboratory settings. These facilities benefit from higher sample volumes, trained personnel, established quality-control systems, and connectivity to laboratory information systems, thereby supporting the efficient use of multi-assay platforms. Point-of-care immunoassay analyzers enable laboratories to reduce turnaround times for cardiac, inflammatory, endocrine, and infectious disease tests while maintaining standardized workflows. For instance, in October 2025, HORIBA India launched the compact Yumizen M300 automated chemiluminescence immunoassay analyzer, extending access to sensitive quantitative testing. Increasing deployment of space-efficient systems in diagnostic laboratories is expected to improve testing capacity, accelerate clinical reporting, and support overall market growth.

Regional Insights

The North America point-of-care immunoassay analyzer market held the largest revenue share of 38.4% in 2025. Regional growth is supported by well-established emergency-care networks, high diagnostic expenditure, advanced healthcare infrastructure, and the widespread adoption of decentralized testing across hospitals, physician offices, urgent-care centers, and outpatient facilities. The substantial burden of cardiovascular diseases, diabetes, infectious diseases, and inflammatory conditions continues to generate demand for rapid biomarker testing near the patient. Strong availability of portable and benchtop analyzers, broad cardiac and infectious-disease assay menus, and integration with laboratory and hospital information systems further support adoption. Favorable reimbursement structures and continued investment in near-patient diagnostic capabilities are expected to sustain demand for point-of-care immunoassay analyzers and associated assay cartridges across the region.

To learn more about this report, Download Free Sample Report

U.S. Point-of-Care Immunoassay Analyzer Market Trends

The point-of-care immunoassay analyzer market in the U.S. accounted for the largest market revenue share in North America in 2025, driven by extensive emergency-care infrastructure, high testing volumes, and early adoption of portable diagnostic systems. Demand is reinforced by the substantial burden of cardiovascular disease and the clinical requirement for rapid cardiac-marker testing. According to the CDC’s National Center for Health Statistics, heart disease caused 683,491 deaths in 2024, while 5.0% of adults had been diagnosed with coronary heart disease. For instance, in January 2025, the U.S. FDA granted 510(k) clearance under K240984 for Abbott’s i-STAT high-sensitivity troponin I cartridge for use with the handheld i-STAT 1 System. The clearance enabled high-sensitivity cardiac troponin measurement near the patient, supporting faster assessment of myocardial infarction and strengthening adoption in acute-care settings.

Europe Point-of-Care Immunoassay Analyzer Market Trends

The point-of-care immunoassay analyzer market in Europe is supported by established healthcare infrastructure, rising cardiovascular disease screening requirements, and expanding adoption of rapid cardiac biomarker testing. Cardiovascular diseases cause approximately 1.7 million deaths and impose economic costs exceeding €282 billion annually across the EU. In December 2025, the European Commission unveiled its Safe Hearts Plan, which includes an EU protocol for cardiovascular health checks and initiatives covering early detection, personalized monitoring, and diagnostic innovation. Although the plan does not specifically mandate point-of-care immunoassay testing, its emphasis on screening and timely diagnosis is expected to support demand for troponin, NT-proBNP, D-dimer, and other near-patient biomarker assays across European healthcare settings.

The UK point-of-care immunoassay analyzer market is driven by efforts to shorten diagnostic pathways, reduce pressure on hospital services, and extend rapid testing into primary and community-care settings. Cardiovascular disease, sepsis, respiratory infections, and chronic-condition monitoring generate sustained demand for near-patient biomarker measurement. According to the Office for National Statistics, ischaemic heart disease accounted for 54,097 deaths in England and Wales in 2024, representing 9.6% of registered deaths. In June 2025, strengthened post-market surveillance regulations entered into force in Great Britain, requiring manufacturers to systematically monitor device safety and performance and respond more rapidly to emerging risks. These requirements increase compliance obligations for immunoassay suppliers but are expected to strengthen confidence in point-of-care systems operated outside centralized laboratories.

The point-of-care immunoassay analyzer market in Germany is expected to grow significantly, driven by a large hospital network, established reimbursement mechanisms, and demand for faster testing of cardiovascular and inflammatory markers. An aging population and substantial cardiometabolic disease burden are supporting analyzer placements across emergency departments, outpatient facilities, and physician practices. Germany’s Federal Statistical Office reported that cardiovascular diseases remained among the country’s principal causes of death in 2024, including 11,718 deaths attributed to hypertensive heart and kidney disease. In January 2025, Germany’s Hospital Care Improvement Act entered into force, introducing 65 service groups with defined staffing, equipment, and departmental requirements. The reform also established intersectoral care facilities to provide outpatient and short-term inpatient services, particularly in rural areas, and provided for a €50 billion transformation fund covering 2026-2035. Although the legislation does not specifically allocate funding to point-of-care immunoassay systems, investments in equipment, cross-sector care, and decentralized service capacity are expected to create procurement opportunities for compact analyzers used for cardiac, inflammatory, and infectious disease testing.

Asia Pacific Point-of-Care Immunoassay Analyzer Market Trends

The point-of-care immunoassay analyzer market in the Asia Pacific region is expected to grow at the fastest CAGR during the forecast period, driven by expanding hospital capacity, large, underserved populations, rising chronic disease prevalence, and increasing investment in decentralized diagnostics. Demand varies considerably across advanced markets and lower-resource healthcare systems, creating opportunities for both high-sensitivity quantitative analyzers and cost-efficient cartridge-based platforms. Cardiovascular disease remains a major public health challenge worldwide. According to the WHO’s July 2025 update, cardiovascular diseases caused an estimated 19.8 million deaths in 2022, accounting for approximately 32% of all global deaths. More than three-quarters of these deaths occurred in low- and middle-income countries. This substantial disease burden, combined with efforts to extend diagnostic services beyond centralized laboratories, is expected to increase demand for accessible cardiac-biomarker testing and support the wider adoption of rapid point-of-care immunoassay analyzers across the Asia Pacific.

The China point-of-care immunoassay analyzer market represents a high-potential growth opportunity, driven by local diagnostic manufacturing, expansion of community healthcare, and increasing demand for rapid cardiovascular, inflammatory, and infectious disease testing. The country’s large population with cardiometabolic diseases creates substantial demand for near-patient biomarker assessment, particularly in lower-tier hospitals and primary care facilities. The national cardiovascular-health framework estimates that approximately 330 million people in China are living with cardiovascular disease. For instance, in March 2025, the National Medical Products Administration revised requirements governing the domestic production of imported medical devices, with the stated objective of simplifying registration materials and accelerating market availability. The policy may facilitate localized production of diagnostic instruments, reduce supply-chain dependence, and encourage multinational manufacturers to establish domestic manufacturing arrangements, although registration and quality-management requirements remain substantial.

The point-of-care immunoassay analyzermarket in Japan is important, supported by an aging population, universal health coverage, advanced diagnostic infrastructure, and demand for efficient testing across hospitals and outpatient facilities. Cardiac, infectious-disease, endocrine, and inflammatory-marker testing represents an established application base for compact immunoassay systems. According to Japan’s finalized 2024 Vital Statistics, heart disease, excluding hypertensive heart disease, caused 226,388 deaths, corresponding to a mortality rate of 188.2 per 100,000 populations. This substantial cardiovascular burden supports sustained demand for rapid troponin, NT-proBNP, D-dimer, and other cardiac-biomarker assays across emergency departments and near-patient settings. Continued adoption of whole-blood testing, automated cartridge-based workflows, and digitally connected analyzers is expected to strengthen market penetration by reducing turnaround times and supporting faster clinical decision-making.

Latin America Point-of-Care Immunoassay Analyzer Market Trends

The point-of-care immunoassay analyzer market in Latin America is emerging, supported by primary-care expansion, uneven access to centralized laboratories, and demand for rapid cardiovascular and infectious-disease testing. Adoption remains concentrated in larger urban healthcare networks, while public procurement constraints and fragmented regulatory systems affect broader penetration. PAHO reported in July 2025 that noncommunicable diseases caused six million deaths in the Americas in 2021, representing 65% of regional mortality, with nearly 40% occurring before age 70. For instance, in 2025, PAHO continued to expand its Better Care for NCDs initiative through primary healthcare systems, including the procurement of cardiovascular medicines and equipment in participating countries. Greater integration of NCD management into primary care is expected to increase demand for rapid biomarker testing, although affordability and distributor coverage remain important constraints on adoption.

Middle East and Africa Point-of-Care Immunoassay Analyzer Market Trends

The point-of-care immunoassay analyzer market in the Middle East & Africa is expected to grow gradually, supported by hospital modernization, expansion of emergency care services, and demand for rapid testing in areas with limited access to centralized laboratories. Gulf countries are adopting compact quantitative analyzers for cardiac, inflammatory, endocrine, and infectious-disease biomarkers, while African healthcare systems require portable, low-maintenance platforms with whole-blood compatibility and affordable single-use cartridges. According to the WHO African Region’s 2024 progress report, approximately 1.6 million adults aged 30-70 die prematurely from major noncommunicable diseases annually, while cardiovascular diseases account for an estimated 1.09 million deaths. This disease burden supports demand for rapid troponin, NT-proBNP, D-dimer, CRP, and related immunoassays. However, constrained laboratory budgets, fragmented regulation, limited reimbursement, and inconsistent access to cartridges and technical support may restrict broader adoption.

Key Point-of-Care Immunoassay Analyzer Company Insights

Leading companies in the point-of-care immunoassay analyzer industry focus on expanding high-value assay menus across cardiac, inflammatory, sepsis, coagulation, endocrine, and infectious-disease applications. Their strategies emphasize shorter turnaround times, whole-blood testing, smaller sample requirements, cartridge-based workflows, automation, and digital connectivity. Established companies leverage large installed bases, regulatory expertise, hospital relationships, and proprietary consumables to generate recurring revenue.

Portfolio expansion through acquisitions is also important, as demonstrated by bioMérieux’s acquisition of SpinChip. Emerging Asian manufacturers compete through affordable fluorescence and compact chemiluminescence platforms, broader distributor networks, and product localization, enabling stronger penetration of decentralized facilities and price-sensitive emerging markets.

Key Point-of-Care Immunoassay Analyzer Companies

The following key companies have been profiled for this study on the global point-of-care immunoassay analyzer market.

• Abbott Laboratories

• F. Hoffmann-La Roche Ltd.

• Siemens Healthineers AG

• Danaher Corporation

• QuidelOrtho Corporation

• bioMérieux SA

• PHC Holdings Corporation

• Boditech Med Inc.

• Guangzhou Wondfo Biotech Co., Ltd.

• Getein Biotech, Inc.

Recent Developments

• In January 2025, Roche received U.S. FDA 510(k) clearance and CLIA waiver for its cobas liat CT/NG and CT/NG/MG STI multiplex assay panels. The PCR-based assays enable simultaneous detection and differentiation of chlamydia, gonorrhea, and Mycoplasma genitalium, providing results in 20 minutes or less for point-of-care testing.

• In March 2025, Visby Medical received U.S. FDA De Novo marketing authorization for its Women’s Sexual Health Test, the first over-the-counter diagnostic test for chlamydia, gonorrhea, and trichomoniasis that can be performed entirely at home. The test uses a self-collected vaginal swab and provides results in approximately 30 minutes.

• In 2026, COWIN GENE launched the Cowingene MG/MH NATBox Detection Kit, a molecular point-of-care diagnostic solution for rapid detection of Mycoplasma genitalium and Mycoplasma hominis. The assay supports urine, urethral, cervical, and vaginal swab specimens and operates on the compact NATBox Mini II platform, strengthening decentralized STI testing capabilities.

• In May 2026, AAZ and En Carta Diagnostics entered into a co-development and commercialization agreement to develop rapid molecular tests and self-tests for chlamydia and gonorrhea. The tests are designed to provide results in under 30 minutes and enable decentralized testing across primary care, pharmacies, and home settings in Europe.

Global Point-of-Care Immunoassay Analyzer Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends and opportunities in each sub-segment from 2021 to 2033. For this study, Grand View Research has segmented the global point-of-care immunoassay analyzer market report based on the type, analyzer type, detection technology, application, end use, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Handheld & Portable Analyzer

  • Compact Benchtop Analyzer

• Analyzer Type Outlook (Revenue, USD Billion, 2021 - 2033)

  • Dedicated Immunoassay Analyzers

  • Multifunction POCT Analyzers with Immunoassay Capability

• Detection Technology Outlook (Revenue, USD Billion, 2021 - 2033)

  • Fluorescence

  • Chemiluminescence

  • Electrochemical

  • Other Detection Technology

• Application Outlook (Revenue, USD Billion, 2021 - 2033)]

  • Cardiac Disease Testing

  • Infectious Disease Testing

  • Inflammation & Sepsis Testing

  • Coagulation & Thrombosis Testing

  • Endocrine & Reproductive Health Testing

  • Diabetes & Metabolic Testing

  • Renal Disease Testing

  • Nutritional & Bone Health Testing

  • Oncology Testing

  • Other Application

• End Use Outlook (Revenue, USD Billion, 2021 - 2033)

  • Hospitals & Clinics

  • Diagnostic Laboratories

  • Research Centers & Academic Institutes

  • Other End Users

• Regional Outlook (Revenue, USD Billion; 2021 - 2033)

  • North America

    • U.S.

    • Canada

    • Mexico

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Norway

    • Denmark

    • Sweden

  • Asia Pacific

    • Japan

    • China

    • India

    • Australia

    • South Korea

    • Thailand

  • Latin America

    • Brazil

    • Argentina

  • Middle East & Africa

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The point-of-care immunoassay analyzer market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is developed through value-chain sizing by reconciling supply-side and demand-side estimates and triangulating the results using bottom-up and top-down approaches. Every estimate undergoes multiple levels of expert validation before publication, with each point-of-care immunoassay analyzer market segment quantified using the revenue-capture definitions presented in the table below.

Estimation Model

The point-of-care immunoassay analyzer industry was estimated by identifying key manufacturers, benchmarking their analyzer portfolios, and assessing product-level revenue across compact benchtop, handheld, dedicated, and multifunction platforms. Technology-level revenues were aggregated and validated against the existing market, installed-base, and patient-testing trends, and the estimated market shares of leading manufacturers to determine the overall market size.

To learn more about this report, Download Free Sample Report